WJPPS Citation Report

Submit Article

Search

News & Updation

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

  • WJPPS: New Impact Factor 2026
  • WJPPS Impact Factor has been Increased to 8.485 for Year 2026.

  • WJPPS: NOVEMBER ISSUE PUBLISHED
  • NOVEMBER 2026 Issue has been successfully launched on 1 NOVEMBER 2026.

Abstract

ECONOMIC VIABILITY OF 6-MONTH BPAL/BPALM REGIMENS VERSUS LEGACY MDR-TB THERAPIES: A SYSTEMATIC REVIEW

Amit Bhattacharjee*, Nikki Tripathi, Shourabh, Kanika, Govind Mohan, Snehpreet Kaur Saini, Tushar Soni

ABSTRACT

This systematic review synthesizes and quantifies evidence regarding the economic viability, cost-effectiveness, and budget impact of 6-month BPaL/BPaLM regimens compared with legacy longer (18–24 months) and shorter (9–11 months) MDR-TB therapies across varied income settings. Multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) presents a severe global health threat, historically managed with 9-to-24-month regimens plagued by poor adherence, severe drug toxicity, and substantial economic toxicity. The introduction of 6-month, all-oral bedaquiline, Pretomanid and linezolid with or without moxifloxacin (BPaL/BPaLM) regimens has redefined clinical management. However, national tuberculosis programs (NTPs) require systematic health economic evaluations to justify programmatic transition. Following PRISMA 2020 and CHEERS 2022 guidelines, peer-reviewed economic evaluation literature was evaluated. BPaL/BPaLM regimens consistently demonstrate economic dominance or high cost-effectiveness across high-burden environments (e.g., South Africa, India, Georgia, Philippines, Moldova, Indonesia, Kyrgyzstan, Nigeria). Direct treatment cost reductions ranged from 20% to 78%, driven by a 60–80% decrease in health service utilization, outpatient monitoring visits, and inpatient bed-days. Budget impact models project overall 5-year programmatic expenditure reductions of 9–32% once scaled, alongside marked decreases in catastrophic household costs.

Keywords: Multidrug resistant tuberculosis, Economic Evaluation, Cost-Effectiveness, Budget Impact Analysis, Regimen.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More